More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
PLAINSBORO, N.J., Dec. 21, 2017 -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced President and Chief Executive Officer Peter Arduini will speak at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, California at 3:30 p.m. PT (6:30 p.m. ET) on Wednesday, January 10, 2018.
A live audio webcast of the presentation will be available on the Investors section of the company’s website at www.integralife.com.
About Integra LifeSciences
Integra LifeSciences (NASDAQ:IART) is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading plastic and regenerative technologies, in specialty surgical solutions and orthopedics and tissue technologies. For more information, please visit www.integralife.com.
Statements made at the upcoming conferences may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to, future financial performance, new product development, governmental approvals, market potential and resulting sales as well as potential therapeutic applications, and additional acquisitions. These risks and uncertainties include market conditions and other factors beyond the Company's control and the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2016 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results. These forward-looking statements are made only as the date thereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations:
Michael Beaulieu
Director, Investor Relations
(609) 750-2827
[email protected]
Media Contact:
Laurene Isip
Senior Director, Global Corporate Communications
(609) 750 7984
[email protected]
